4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard

PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,

PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

PURCHASE, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, will be presenting biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference taking place April 1-5, 2025 in Vienna, Austria. Mary Hamby, Ph.D., Cognition Therapeutics' VP of research will present findings from the SHINE study during a podium presentation at the conference. Her address will focus on the analysis of key proteins, called biomarkers, that were

Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year en

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through March 18th. To facilitate investor relations scheduling and to view a complete calend

PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access:  US/Canada Toll-Free Dial-in Number: (877) 704-4453International Dial-In Number: (201) 389-0920Conference I

PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), was notified by the Nasdaq Stock Market LLC ("Nasdaq") on September 12, 2024 that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days. As a result, Cognition was given 180 calendar days to regain compliance with the minimum bid price requirement, by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. The period to regain compliance with the minimum bid price require

NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT:   https://bit.ly/4hnure6 It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "We look forward to bringing together innovators from the life sciences sector," s

PURCHASE, N.Y., March 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), announced that President and CEO Lisa Ricciardi will present live at the Life Sciences Virtual Investor Conference on March 13, 2025 at 9:30 a.m. ET. In her presentation, Ms. Ricciardi will review plans for 2025 to support the advancement of zervimesine (CT1812) in Alzheimer's disease and dementia with Lewy bodies following the Company's positive Phase 2 data readouts. This will be a live, interactive, online event. Members of the manageme

PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") announced the publication of a manuscript reviewing recent work supporting the potential of zervimesine (CT1812), a small molecule drug candidate to treat dry age-related macular degeneration (dry AMD). The Journal of Nature Scientific Reports has published the paper online: https://www.nature.com/articles/s41598-025-87921-9. Several separate studies were conducted and are reported in this manuscript: a)  an analysis of cerebrospinal fluid (CSF) collected from participants of two Alzheimer's

Masked Analysis Shows Participants Receiving Oral Zervimesine for at Least 6 Months Experienced Slower Lesion Growth than Participants Receiving Placebo Following the Futility Analysis, Management Concluded the Phase 2 Study, Preserving Capital Full Analysis will be Provided in the Second Quarter of 2025 PURCHASE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported a positive outcome of an analysis of masked data from the ongoing ‘MAGNIFY' Phase 2 trial of zervimesine (also known as CT1812) in adults with geographic atrophy (GA) secondary to dry age-related macular

PITTSBURGH, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review methods of screening participants for clinical trials to ensure that the patients selected are most likely to benefit from treatment. Dr. Hamby will present an overview of the findings from Cognition's Phase 2 ‘SHINE' study of zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. Participants with low

Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year en

PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access:  US/Canada Toll-Free Dial-in Number: (877) 704-4453International Dial-In Number: (201) 389-0920Conference I

- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeutic responses ac

- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition") today reported financial results for the third quarter ended September 30, 2024, and provided a business update. "In the th

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology -  - ADAS-Cog 11 scores showed 95% slowing of decline -  - MMSE scores showed 108% slowing of decline -  - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 -  - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented a pre-specified analysis of data fro

- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - PURCHASE, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "We announced favorable resul

PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference CallDate / TimeAugust 8, 2024 at 8:30am ET / 5:30am PTTelephone Access: US/Canada Participant Toll-Free Dial-in Number: (800) 715-9871U

PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update. Conference Call Information: Telephone Access:  US/Canada Participant Toll-Free Dial-in Numb

Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer's Disease Commenced Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer's Disease Published Data from SNAP Study Affirming Target Engagement of Sigma-2 (σ-2) Receptor Patient Dosing Commenced in MAGNIFY Study for Geographic Atrophy PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the "Company" or "Cognition"), today reported financial results for the second quarter ended June 30, 2023 an

PURCHASE, N.Y., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter on Tuesday, August 8, 2023 before the market opens. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review financial results and provide a business update. Conference Call Information: Telephone Access:  US/New York Participant Dial-in Number: (646) 307-1963US/Canada Participant Toll-Free Dia